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The provision of oxygen to tissues depends on hemoglobin, requiring 
the coordinated expression of several globin chains that form func-
tional tetramers. An index of the importance of hemoglobin function 
is the evolutionary duplication and divergence of regulation of globin 
gene copies to adapt to stages of development and buffer the effects 
of mutational loss. In particular, at birth, a switch occurs from fetal 
hemoglobin (HbF) to hemoglobin A2 (HbA2) and hemoglobin A1 
(HbA1), such that during adult life the hemoglobin forms comprise 
~1% HbF, ~3% HbA2 and ~96% HbA1. The different hemoglobins 
all contain α-globin chains, encoded by two eponymous genes (HBA1 
and HBA2) on chromosome 16. These chains aggregate with non– 
α-globin chains encoded by HBG1 and HBG2 (for γ-globin; HbF), 
HBD (for δ-globin; HbA2) and HBB (for β-globin; HbA1) genes in 
the β-globin gene cluster on chromosome 11 (Fig. 1). The molecular 
switch between fetal and adult hemoglobin occurs via the binding of 
transcription factors to regulatory DNA sequences controlling the 
expression of globin genes. In particular, the various genes in the 
β-globin cluster are sequentially activated during ontogeny, such that 
time-specific expression patterns follow the genomic order1.
Inherited disorders of hemoglobin, such as β-thalassemia, which 
is caused by mutations at the HBB (hemoglobin β) locus, represent 
the most common monogenic disorders worldwide2. The prevalence 
of these disorders is highest in areas where malaria was or remains 
endemic3. The severity of inherited hemoglobin disorders is also 
variable, from severe, lifelong transfusion-dependent anemia to mild 
anemia that does not require transfusion, depending on the molecular 
defect and genotype status as well as ameliorating variants in modifier 
genes. Therefore, studying the genetic regulation of hemoglobin lev-
els might identify new factors involved and mechanisms to optimize 
strategies for therapy.
The large heritable contribution to phenotypic variance in HbA2 
and HbF in the general population (0.728 and 0.633, respectively; 
Online Methods and a previous report4) indicates that genetic analy-
ses could lead to new insights. In genome-wide association studies 
(GWAS), two genomic regions, the β-globin gene cluster and the 
HBS1L-MYB locus, have been associated at a genome-wide sig-
nificance level with variations in the amount of HbA2 (ref. 5), and 
only these loci and BCL11A have been associated with HbF levels6,7. 
Variants at all four loci are powerful modifiers of the severity of 
β-thalassemia and sickle-cell disease7–10. Notably, none of the variants 
associated with HbA2 or HbF levels have been found to be associated 
with total hemoglobin levels, even in the largest meta-analysis of over 
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135,000 individuals11. This indicates that, in analyses of total hemo-
globin levels, the association signals for the subtypes are diluted and 
possibly obscured by opposite directions of effect. Currently, most of 
the heritability for variance in HbF and HbA2 levels also remains to 
be explained, and variation in HbA1 levels has not been specifically 
assessed by GWAS.
A promising source of genetic data to extend analyses is the founder 
Sardinian population, in which associations have previously been 
detected in a large cohort through the analysis of data from geno-
typing arrays bearing common and ubiquitous variants7. Here we 
extend these analyses to rare and Sardinian-specific variants inferred 
from whole-genome sequencing of 2,120 Sardinians (Supplementary 
Fig. 1 and Supplementary Note). Furthermore, analyzing variants 
modulating HbA1, HbA2 and HbF levels concurrently in a single 
cohort provides a route to assess associations that overlap for differ-
ent hemoglobin forms without the need to account for differences in 
study size, ancestry or measurements.
RESULTS
To test for genetic associations with the levels of HbA1, HbA2 and 
HbF, we interrogated ~10.9 million SNPs, genotyped or imputed in 
6,602 general population volunteers of the SardiNIA longitudinal 
study4 (Online Methods and Supplementary Table 1).
Initial analyses showed a predominant role for the HBB c.118C>T 
mutation introducing a premature stop codon (p.Gln40*), bet-
ter known as the β039 mutation, a variant common in Sardinia 
(rs11549407: allele frequency = 4.8%). This mutation results in 
complete absence of β-globin chain synthesis (β0) and consequent 
β-thalassemia in homozygous individuals and results in a decrease 
in HbA1 levels and an increase in HbA2 and HbF levels in hetero-
zygous individuals (P < 1.0 × 10−200). Because its effect had been 
established previously7,12, we considered this mutation and other 
rarer β0 mutations in β-thalassemia known in Sardinia as covariates 
(Online Methods and Supplementary Table 2). The assessed indi-
viduals in the cohort included 664 healthy heterozygous carriers of 
β0 mutations but no individuals with β-thalassemia.
The genome-wide scan identified 23 unique variants at 10 loci at 
the classical significance threshold of P = 5 × 10−8. Of note, 21 loci 
were significant even when considering a more stringent threshold 
of P = 1.4 × 10−8, calculated on the basis of an empirical estimate of 
the number of independent tests in the Sardinian genome (see the 
companion paper13).
Five variants were at previously undetected loci, four variants were 
new, independent signals at known loci and ten variants refined pre-
viously described associations to new lead polymorphisms that may 
have functional effects (Table 1). We observed 6, 14 and 8 independ-
ent genome-wide significant signals for HbA1, HbA2 and HbF levels, 
respectively (Supplementary Fig. 2). Hence, some of the associated 
variants significantly affected more than one hemoglobin, resulting 
in 28 variant-trait associations (Fig. 2, Table 1 and Supplementary 
Table 3). Variants resulting from imputation and not supported by 
data for linked genotyped markers were experimentally validated 
(Supplementary Table 4).
New	associations	at	newly	associated	loci
New associations were detected for all three hemoglobin forms. For 
HbA1, we observed a signal led by chr12:123681790 (in an intron 
of MPHOSPH9), encompassing several SNPs in complete linkage 
disequilibrium (LD) in a region with several genes (Supplementary 
Fig. 3). Which gene is truly associated and how it affects hemoglobin 
production remain unclear, although, among the top associated SNPs, 
a variant in an intron of ARL6IP4 (chr12:123465483) falls in a highly 
conserved region rich in putative transcription factor binding sites 
and had the highest score for in silico prediction of deleterious impact 
on function (combined annotation-dependent depletion (CADD) 
score)14, as detailed in Supplementary Table 5. Although this associa-
tion was just below the more stringent empirical threshold of signifi-
cance, it was further strengthened by independent association with 
another hemoglobin form (HbA2, P = 5.9 × 10−5) (Table 1).
For HbA2, we identified three new signals. One, rs141006889, is 
a missense variant located in ZFPM1, a gene also known as FOG1 
that encodes a cofactor of the hematopoietic transcription factors 
GATA1 and GATA2 (ref. 15; Supplementary Fig. 4). The complexes 
formed by FOG1 and GATA proteins are essential for normal eryth-
roid differentiation15, as demonstrated by pathogenetic mutations that 
abrogate the FOG1-GATA interaction to cause familial dyserythro-
poietic anemia and thrombocytopenia16. Another signal was defined 
by a pair of statistically indistinguishable variants, rs113267280 
and rs112233623 (P = 1.11 × 10−29 and 1.29 × 10−29, respectively), 
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Figure 1 Association at the globin gene clusters. (a,b) Schematics of the 
association results in the genomic context of the β-globin (a) and α-globin 
(b) gene clusters. For each hemoglobin form, the positions of the associated 
markers are indicated, with plus and minus signs indicating an increase or 
decrease in the levels of the corresponding hemoglobin form with the effect 
allele (as in table 1). The symbol is larger if the marker is associated at the 
genome-wide level or smaller if the association results from the analysis of 
pleiotropic effects. The β039 mutation and –α 3.7 type I deletion as well 
as relevant genes and the locus control region hypersensitivity (HS) sites 
are indicated. Finally, at the bottom of each panel is presented the LD (r2) 
profile for the region in Sardinia, with colors representing a range of LD 
from high (red) to intermediate (green) to low (blue).
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located in the CCND3 gene, whose product, cyclin D3, is thought to 
be critical for erythropoiesis17. Knockdown of Ccnd3 correlates with a 
reduction in the number of cell divisions during terminal eryth-
ropoiesis, thereby resulting in the production of fewer red blood 
cells that are larger in size18. These variants are also in partial 
LD with rs9349205 (r2 = 0.40), a SNP previously associated with 
mean red blood cell volume and number (Supplementary Table 6), 
which is located 160 bp away from rs112233623 in the same 
table 1 Most significant independent association results from single-variant tests for A1, A2 and fetal hemoglobin
Trait (units) and 
locus number Candidate gene
Chromosome:
position
rsID from  
dbSNP 142
Alleles  
(EA/OA) RSQR EAF Effect (SE) P value
Shared effects
HbA1 HbA2 HbF
HbA1 (g/dl)
 Locus 1a α-globin gene cluster  
(p, o, b); MPG (p)
16:149539a,d,f rs570013781 A/G 0.98 0.136 −0.1995 (0.023) 5.86 × 10−18 − − −
α-globin gene cluster  
(p, o, b); AXIN1 (p)
16:391593 
(cond.)a,c,e
– t/c 0.94 0.012 −0.4028 (0.058) 3.28 × 10−12 − −
 Locus 2 FAM3A (p); G6PD  
(p, c, o, b); IKBKG (p)
X:153762634d,f rs5030868 A/G Genotyped 0.085 −0.1256 (0.019) 2.78 × 10−11 −
 locus 3b MPHOSPH9 (p) 12:123681790b – A/c 0.96 0.010 −0.3606 (0.064) 1.68 × 10−8 − −
HbA2
 Locus 1 (%)d β-globin gene cluster  
(p, o, b); HBD (c)
11:5255582d,f rs35152987 A/C Genotyped 0.004 −2.182 (0.109) 4.35 × 10−86 −
β-globin gene cluster  
(p, o, b); HBD (c)
11:5251849 
(cond.)d,f
rs7944544 T/G 0.98 0.005 −1.26 (0.097) 3.90 × 10−38 − +
β-globin gene cluster  
(p, o, b); HBB (c);  
HBG1-HBG2 (e);  
OR51V1 (p)
11:5231565 
(cond.)d,f
rs12793110 T/C 1.00 0.181 −0.2408 (0.019) 5.75 × 10−36 − −
β-globin gene cluster  
(p, o, b); OR51V1 (p)
11:5242698 
(cond.)d,f
rs11036338 C/G 0.99 0.381 0.1282 (0.017) 2.03 × 10−14 +
β-globin gene cluster  
(p, o, b); HBG1-HBG2 (e)
11:5250168 
(cond.)d,f
rs7936823 G/A 0.96 0.466 0.1117 (0.015) 5.00 × 10−13 + + +
 Locus 2 (g/dl)a,c,e α-globin gene cluster  
(p, o, b); HBM (c);  
LUC7L (p)
16:216593a,c rs141494605 c/t 0.97 0.149 −0.3080 (0.025) 3.94 × 10−35 − − −
α-globin gene cluster  
(p, o, b); AXIN1 (p)
16:391593  
(cond.)a,c,e
– t/c 0.94 0.012 −0.5112 (0.063) 6.48 × 10−16 − −
α-globin gene cluster  
(p, o, b); ARHGDIG (p); 
AXIN1 (p); ITFG3 (p);  
PDIA2 (p); RGS11 (p)
16:342218 
(cond.)a,c,e
rs148706947 t/c 0.93 0.021 0.2892 (0.051) 1.04 × 10−8 +
 locus 3 (%)b CCND3 (p, b) 6:41952511b rs113267280 G/t 0.99 0.101 0.2923 (0.026) 1.11 × 10−29 + +
 Locus 4 (%) MYB (b) 6:135418916 rs7776054 G/A Genotyped 0.210 0.1762 (0.020) 3.71 × 10−19 + +
 locus 5 (%)b CTSA (p); PCIF1 (p, c); 
PLTP (p, e); MMP9 (e); 
TNNC2 (e)
20:44547672b rs59329875 c/t 1.00 0.134 −0.1399 (0.024) 3.64 × 10−9 −
 locus 6 (%)b FOG1 (p, b, c);  
C16orf85 (p)
16:88601281b rs141006889 G/A Genotyped 0.007 −0.5074 (0.087) 5.33 × 10−9 −
HbF (g/dl)
 Locus 1 BCL11A (p, o, b) 2:60720951 rs4671393 A/G 1.00 0.136 0.578 (0.023) 2.60 × 10−130 +
BCL11A (p, o, b) 2:60710571 
(cond.)d,f
rs13019832 A/G 1.00 0.484 −0.2024 (0.017) 9.12 × 10−33 −
 Locus 2 MYB (b) 6:135419018 rs9399137 C/T Genotyped 0.205 0.4202 (0.020) 1.09 × 10−93 + +
HBS1L (p, c, e);  
ALDH8A1 (e)
6:135356216 
(cond.)d
rs11754265 c/G 1.00 0.367 −0.1421 (0.021) 5.04 × 10−12 −
 Locus 3d β-globin gene cluster  
(p, o, b); HBG1-HBG2 (e)
11:5290370d rs67385638 G/C 1.00 0.236 0.2038 (0.019) 1.09 × 10−25 +
β-globin gene cluster  
(p, o, b); HBG1-HBG2 (e)
11:5277236 
(cond.)d,f
rs2855122 C/T 1.00 0.395 −0.1458 (0.022) 2.57 × 10−11 + + −
 locus 4b,e NFIX (p) 19:13121899b,e rs183437571 t/c 0.97 0.010 0.4607 (0.081) 1.61 × 10−8 +
The table shows the most significant association results (all results are corrected for β0 mutations observed in the HBB gene, and results for the α-globin gene cluster are adjusted 
for –α 3.7 deletion type I; Online Methods). New signals are shown in bold. At each locus, we indicate the chromosome and genomic position (hg19 build), the rsID when avail-
able, the effect allele tested for association (EA) and the other allele at the SNP (OA), the imputation accuracy (RSQR), the SNP effect allele frequency (EAF) and the regres-
sion coefficients (with standard error, SE). We indicate when a SNP is also linked to the other hemoglobin forms (P < 0.01) and specify the direction of the effect for the allele 
indicated in the EA column (+, increases hemoglobin levels; −, decreases hemoglobin levels). The candidate genes likely to be modulated by the lead SNP are also reported along 
with their inclusion criteria, as described in the Online Methods (p, position; c, coding; e, eQTL; o, Online Mendelian Inheritance in Man (OMIM); b, biological). When the α-globin 
gene cluster is mentioned, we are referring to the NPRL3, HBZ, HBQ1, HBA1, HBA2 and HBM genes; when the β-globin gene cluster is mentioned, we are referring to the HBB, 
HBD, HBBP1, HBG1, HBG2 and HBE1 genes. Association coefficients for males and females separately are reported in supplementary table 11. Cond., results obtained by condi-
tional analysis including as covariates the markers from the row(s) above for the considered locus.
aAssociation results locally corrected for –α 3.7 deletion type I (g.34164_37967del3804, NG_000006.1) (supplementary Note). bFirst time associated with the trait and in a new locus.  
cFirst time associated with the trait in a previously reported locus. dSignal refinement at a previously reported signal. eResult not found using the 1000 Genomes Project reference panel. fVariant 
refining previously reported signals.
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Figure 2 Diagrams of genome-wide associated loci. (a,b) Representations of genome-wide significant findings for hemoglobin levels in relation to their 
contribution to the phenotypic variation (variance explained) (a) and their individual impact (effect size) (b). At each level, the length of the black bar 
represents the magnitude of the variance explained (a) or the effect size (b) for each trait, locus, gene and variant. The bars are connected by colored 
bands to their subcomponents (loci for each trait, genes for each locus, variants for each gene). Three colors (yellow, green and blue) represent the 
three hemoglobin forms (HbA1, HbA2 and HbF, respectively); for loci or genes affecting more than one hemoglobin, gray indicates effects shared by 
HbA1 and HbA2, cyan indicates effects shared by HbA2 and HbF, and light gray indicates effects shared by all three hemoglobin forms. Each panel is 
drawn to show loci in order of their importance, from the largest to smallest amount of explained phenotypic variance (a) or effect size (b). The variance 
explained by each locus was calculated by fitting a regression model including all variants at that locus, and the effect size for each locus is the sum 
of the effect sizes of all the variants in that locus (supplementary table 3 reports the effect sizes for such joint models). For variants associated with 
more than one trait, the maximum value was used. Markers are reported using chromosome:position notation when an rsID was not available; when an 
intergenic region was involved, we show nearby genes in parentheses instead of indicating a single gene for the locus.
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erythroid-specific enhancer functionally associated with CCND3 
(refs. 18–20). rs112233623 was also the associated variant with the 
highest CADD score (Supplementary Table 5).
An additional variant related to HbA2, rs59329875, was observed 
for the first time in this study. It is situated between PLTP, which 
has been associated with several plasma lipoprotein and triglyceride 
levels21–24, and PCIF1, which is thought to negatively regulate gene 
expression by RNA polymerase II (ref. 25).
For HbF, we identified one new variant associated with its levels: 
rs183437571, located on chromosome 19 in an intron of NFIX, which 
encodes a CCAAT-binding transcription factor. The association for 
this variant was just below the empirical significance threshold of 
P = 1.4 × 10−8 but is supported by considerable biological evidence 
implicating the gene and the surrounding region in hemoglobin 
regulation. Specifically, rs183437571 falls in a CpG region that is dif-
ferentially methylated in fetal and adult red blood cell progenitors26. 
In mice, Nfix was recently identified as one of the regulatory factors 
with relatively restricted expression in hematopoietic stem cells27 and 
was required for the survival of hematopoietic stem and progenitor 
cells during stress hematopoiesis28. Intriguingly, NFIX is situated in 
a region of ~300 kb that encompasses a number of genes involved 
in erythropoiesis (DNASE2 and KLF1)29–33 or otherwise associated 
with red blood cell traits, including mean corpuscular hemoglobin 
levels (SYCE2, FARSA and CALR)11 (Supplementary Fig. 5 and 
Supplementary Table 6). KLF1 is a particularly interesting candidate 
gene33,34, but the mutations observed in previous studies35 were not 
found and the gene itself is situated in an LD block distinct from the 
one corresponding to our association signal. However, long-distance 
regulatory interactions remain a possibility.
Of the five new signals, the discovery of chr12:123681790 for HbA1, 
rs141006889 for HbA2 and rs183437571 for HbF was strongly influ-
enced by the assessment of variants from Sardinian whole-genome 
sequencing. Specifically, chr12:123681790 was missing from 1000 
Genomes Project phase 3 data36, and, when using this public refer-
ence panel, the signal was misplaced at another variant ~1 Mb away; 
rs141006889 was included in the design of one genotyping array 
(ExomeChip) after it was identified through our sequencing effort 
but is currently not detected in sequenced 1000 Genomes Project 
samples; and rs183437571 was poorly imputed with 1000 Genomes 
Project phase 3 data, with a resulting signal that was not genome-wide 
significant (Table 1 and Supplementary Table 7).
Overall, the amount of variance explained by markers associated at 
the genome-wide level (Table 1) accounted for a fraction of the esti-
mated genetic component for each trait (ranging from 46% for HbA1 
to 68% for HbA2; Online Methods), supporting inheritance models 
that include variants that have small effect sizes and/or are rare. For 
instance, 21 additional genes with signals showing suggestive levels of 
significance (P < 1 × 10−4, minor allele frequency (MAF) >0.5%) were 
related to the genome-wide significant loci listed here, either in the 
scientific literature (PubMed records before 2006) or by expression 
levels (Human Expression Atlas37) or Gene Ontology38 categories, as 
determined using GRAIL software39 (Supplementary Table 8 and 
Supplementary Note). Four of the suggestive signals most strongly 
linked to genome-wide association findings were located in NFE2, 
which encodes erythroid nuclear factor 2 (ref. 40); ADGB, which 
encodes a recently discovered globin of unknown physiological func-
tion41; and SPTB and ANK1, both of which encode proteins affecting 
the stability of erythrocyte membranes42.
To test for replication of the associations at new loci detected in 
Sardinians, we used the largest independent sample reported thus far, 
which measured HbA2 and HbF levels as well as F cell percentage 
(the proportion of erythrocytes containing HbF) (Online Methods) 
in 4,131 individuals from the TwinsUK cohort enrolled from the 
UK general population43. For two loci, both associated with HbA2 
levels, we successfully replicated the associations seen in Sardinia. 
Specifically, we observed a P value of 6.98 × 10−6 for rs59329875 in 
the PLTP-PCIF1 intergenic region (MAF = 0.18) and a P value of 1.73 
× 10−4 for rs113267280 in CCND3 (MAF = 0.01). The rarity of other 
variants precluded replication. The MPHOSPH9 and FOG1 variants 
associated with HbA1 and HbA2 levels, respectively, are missing in 
publicly available imputation panels, and rs183437571 in NFIX, which 
associated with HbF levels in Sardinia, was imputed as monomorphic 
in the TwinsUK cohort (Table 2 and Online Methods).
Fine	mapping	at	known	loci
The integration of variants from whole-genome sequencing in the 
scan was also instrumental in refining signals at previously known 
loci, either identifying a better lead variant or indicating new inde-
pendent signals. Specifically, we refined the associations within the 
α- and β-globin gene clusters for all three hemoglobins; the associa-
tion of the HBS1L-MYB intergenic region with HbA2 and HbF; and 
the association of the BCL11A gene with HbF.
table 2 replication of new loci
Trait (units) 
and locus 
number SNP
Candidate  
gene
INFO  
score
Alleles  
(EA/OA) EAF
Effect  
(SE) P value Notes
HbA1 (g/dl)
 Locus 3 chr12:123681790 MPHOSP9 _ _ _ _ _ Not imputable because absent in the 
1000 Genomes Project; at the  
moment, Sardinian specific
HbA2 (%)
 Locus 3 rs113267280 CCND3 0.843 G/T 0.011 0.442 (0.118) 1.73 × 10−4 .
 Locus 5 rs59329875 PLPT-PCIF1 0.994 C/T 0.185 0.132 (0.029) 6.98 × 10−6
 Locus 6 rs141006889 FOG1 _ _ _ _ _ Not imputable because absent in the 
1000 Genomes Project; detected in 
the NHLBI GO Exome Sequencing 
Project (ESP)
HbF (%)
 Locus 4 rs183437571 NFIX 0.294 T/C 0.000 _ _ Imputed as monomorphic in the 
TwinsUK cohort
The table describes association in the TwinsUK cohort (n = 4,131 individuals). For each SNP, we indicate the associated hemoglobin tested, the imputation accuracy according to 
the IMPUTE INFO metric, the effect allele tested for association (EA) and the other allele at the SNP (OA), the SNP effect allele frequency (EAF) and the regression coefficients 
(with standard error, SE). The last column explains why some SNPs were not tested. The information in the first column is presented as in table 1.
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The associations within the β-globin gene cluster were intricate. 
As reported above, the strongest modifier in this region is the HBB 
β039 variant, which acts on all three hemoglobin types (Fig. 1, Online 
Methods and Supplementary Table 2). Multiple additional independ-
ent signals were observed in conditional analyses for HbA2 and HbF, 
but they were distinct for each hemoglobin type, highlighting differ-
ent regulatory patterns within the β-globin gene cluster. Specifically, 
for HbA2, we confirmed two known independent associations at 
missense mutations in the HBD gene (rs35152987 and rs35406175; 
the latter was perfectly tagged by our lead signal; Supplementary 
Table 5). In addition, we identified three new independent signals 
(rs12793110, rs11036338 and rs7936823) within an LD block encom-
passing the HBB gene, confirming a controlling role for this region in 
HbA2 production5 (Fig. 1 and Supplementary Fig. 4). For HbF, two 
new independent signals were detected in a separate LD block of the 
β-globin gene cluster (Fig. 1 and Supplementary Fig. 5). The first, 
situated in an intron of the HBE1 gene (rs67385638), remained associ-
ated even when taking into account 43 other variants in the β-globin 
gene cluster associated with hemoglobin variation (Supplementary 
Note). The second was located in a cyclic AMP response element 
upstream of HBG2 (rs2855122) already implicated in drug-mediated 
HbF induction by butyrate44: the different features of this marker 
make it a strong candidate in modulating fetal to adult hemoglobin 
switching (Supplementary Note).
At the α-globin gene cluster, two variants were associated with 
HbA1 and three variants were associated with HbA2, of which one 
affected both traits (Fig. 1 and Table 1). All results at this locus were 
corrected for any effect of the most frequent α-globin gene deletion 
present in Sardinia (g.34164_37967del3804 (NG_000006.1), known as 
–α 3.7 deletion type I), directly genotyped in a subset of the volunteers 
and imputed for the rest of the cohort (Online Methods). This deletion 
was associated at the genome-wide level with both HbA1 and HbA2 
levels but only nominally with HbF levels (Table 1 and Supplementary 
Table 2). The most strongly associated signals (rs570013781 and 
rs141494605) were situated within the NPRL3 and HBM genes, 
affecting HbA1 and HbA2 levels, respectively. NPRL3 contains sev-
eral hypersensitive sites involved in regulation of the α-globin genes. 
HBM encodes a globin member of the avian α-D family45; its expres-
sion is highly regulated in human erythroid cells, although the protein 
has not been detected in human erythroid tissues. These observations 
suggest a possible regulatory function for which high-level protein 
expression would not be required45. An independent variant associ-
ated with HbA1 and HbA2 (chr16:391593) was observed in the AXIN1 
gene, in which a further independent SNP (rs148706947) was found to 
be associated with HbA2 alone (Supplementary Figs. 3 and 4).
We also examined variants in the HBS1L-MYB intergenic region 
known to be associated with HbF and HbA2 levels5. We confirmed 
the role of the known variant (rs66650371, a TAC deletion) on the 
expression of both forms of hemoglobin46,47 (Supplementary Note). 
A further new independent signal for HbF was found at rs11754265 
in an intron of HBS1L, which has been shown to be a much stronger 
expression quantitative trait locus (eQTL) than rs66650371 for HBS1L 
and the neighboring ALDH8A1 gene in monocytes48.
In line with previous studies6–8,49,50, the second intron of BCL11A 
gave multiple signals of association with HbF levels. These can be 
explained by the joint action of variants from each of two independent 
groups of statistically indistinguishable SNPs: one group constitutes 
rs4671393, rs766432 and rs1427407, with P values between 2.6 × 
10−130 and 5.6 × 10−129, and the other group constitutes rs13019832 
and rs7606173, with P values of 6.1 × 10−33 and 9.1 × 10−33, respec-
tively, in our cohort. The most likely causal candidate in the first 
group is rs1427407, a variant already associated with HbF levels in 
other population cohorts and functionally associated with BCL11A 
regulation51. In the second group, we can point to rs13019832 as the 
candidate causal variant, as this SNP had the highest functional CADD 
score (Supplementary Table 5). This variant has also been correlated 
in adipose tissue with the methylation of a CpG site (cg23678058) in 
a region that is functionally associated with BCL11A expression52 
and shows evidence of an effect on GATA-1 binding in peripheral 
blood–derived erythroblasts53,54.
Pleiotropic	effects
Among our 23 lead variants, 6 were associated (with at least P < 0.01) 
with a second hemoglobin type, and another 6 (including β039 
and –α 3.7 deletion type I) were associated with all 3 hemoglobin 
forms (Fig. 1 and Table 1). Overall, all but three pleiotropic variants 
modulated different hemoglobins in the same manner, that is, with 
the same allele increasing the levels of all associated hemoglobins. 
The three exceptions included the β039 variant, which decreased 
HbA1 levels while increasing HbA2 and HbF levels, and two SNPs 
mapping to the β-globin gene cluster, both affecting HbA2 and HbF 
levels but in opposite directions (Fig. 1 and Table 1). Moreover, many 
of the additional suggestive signals were associated with more than 
one hemoglobin type, increasing the likelihood that they are true 
signals (Online Methods). In fact, 14 of these variants—all sharing 
effects on HbA1 and HbA2 levels but none having effects on HbF lev-
els—showed between-trait combined P values that were genome-wide 
significant (Supplementary Table 9) and hint at additional pathways 
of potential interest in hemoglobin dynamics.
In general, the extended number of genetic variants showing joint 
association with HbA1 and HbA2 rather than HbF is consistent with 
high correlations of the levels of the adult hemoglobins HbA1 and 
HbA2 but only partial correlations of these hemoglobin forms with 
the levels of HbF (Online Methods).
Given the central role of hemoglobin in providing oxygen to body 
tissues and the substantial fraction of total body cells accounted for 
by circulating red blood cells, factors influencing hemoglobin produc-
tion and red blood cell count unsurprisingly have pleiotropic effects 
on other non-hematological traits. This is exemplified by the strong 
impact of the major β039 mutation on cholesterol and low-density 
lipoprotein (LDL) cholesterol levels (see the companion paper13). 
Here we extended the analysis for this mutation to 69 non-hemato-
logical quantitative traits selected from among those assessed in the 
SardiNIA cohort4 (Supplementary Note). We found that this vari-
ant was also significantly associated with increased total white blood 
cell counts (P = 3 × 10−7), with the major contribution coming from 
neutrophil counts (P = 1 × 10−6), and platelet counts (P = 9 × 10−5) 
(Supplementary Table 10).
DISCUSSION
We provide evidence for 23 associated variants at 10 loci influenc-
ing the levels of one or more of the 3 hemoglobin species measur-
able in postnatal life. Our results are based on a cohort from the 
Sardinian founder population that is much larger than the samples 
in previously described GWAS for HbF and HbA2, and the analy-
sis interrogates a high-resolution genetic map based on population 
sequencing that expanded the assessed spectrum of allelic variants 
by tenfold in comparison to previous studies. The finding that two 
of the five newly reported loci were not detectable without using 
the SardiNIA reference panel and that the others were mislocalized 
(Table 1 and Supplementary Table 7) further highlights how 
large-scale sequencing efforts in this founder population can identify 
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functionally relevant variants that may be very rare and hence missed 
in other populations.
For the same reasons, however, replication of the results for such 
variants or translation of findings directly into other populations is dif-
ficult. For example, the other currently reported sample of comparable 
size, from the UK, could provide replication only for the two variants 
present there. Similar limitations will likely be found in other GWAS 
designed to detect the effects of rare and founder variants. However, 
additional corroboration of our findings for such variants comes from 
their independent associations with other hemoglobin species and 
hematological traits in Sardinians and also from the biological func-
tions of the genes involved. For instance, variant chr12:123681790 in 
MPHOSP9, associated with HbA1 levels, also shows suggestive evi-
dence of association with HbA2 levels. The variant in FOG1, which is 
very rare in Europeans (MAF = 0.4%), is a missense variant in a gene 
implicated in erythropoiesis, and the variant in NFIX, which is absent 
in other European populations, falls within a cluster of genes involved 
in erythropoiesis and in a CpG region differentially methylated in fetal 
and adult red blood cell progenitors26.
By carrying out GWAS analysis for HbA1, HbA2 and HbF levels 
assessed, to our knowledge, for the first time in the same individuals, 
we see a wide range of pleiotropic effects of variants across the three 
hemoglobin types (Table 1). Strikingly, HbA2 is associated with more 
than half of the loci discovered here (Fig. 2), with many of the loci 
having pleiotropic effects on HbA1 and some having such effects on 
HbF. Thus, although HbA2 has a minor role in the transport of oxygen 
to tissues55, variations in its levels participate in pathways that regu-
late the amounts of the other hemoglobins active in postnatal life.
The direction of the pleiotropic effects among the different hemo-
globin types provides some additional clues to mechanism. Within 
the α-globin gene cluster, in agreement with the presence of α-globin 
chains in HbA1, HbA2 and HbF, all variants affecting more than one 
hemoglobin show the same direction of effect on all. The regulation 
of globin chains from the β-globin gene cluster, however, is more 
complicated. It involves variants with the same direction of effect for 
all hemoglobins (rs7936823) and other variants most likely involved 
in switching mechanisms that affect fetal and adult hemoglobins in 
opposite directions (rs2855122). Still other variants change the kinet-
ics of competition among non–α-globin chains; for example, the β039 
mutation decreases β-globin levels and thereby increases the availabil-
ity of α-globin chains for combination with δ- and γ-globins, leading 
to higher levels of HbA2 and HbF.
Variants influencing only two forms of hemoglobin acted mainly in 
the same direction and never jointly affected HbA1 and HbF levels. 
Among these variants, those shared only by HbA2 and HbF can be 
attributed to specific cis-regulatory mechanisms in the β-globin gene 
cluster (rs12793110 and rs7944544) or to loci with a role in erythroid 
differentiation (CCND3 and MYB). By contrast, variants shared by 
HbA2 and HbA1 either acted in trans (in MPHOSPH9) or were local-
ized to the α-globin gene cluster but with effect sizes probably too 
small to influence HbF production. Consistent with the latter possibil-
ity, –α 3.7 deletion type I, which has strong genome-wide significant 
effects on HbA1 and HbA2, had much smaller only suggestive effects 
on HbF (Supplementary Table 2).
Our analyses also detected broader pleiotropic effects, most strik-
ingly for the β039 variant. In addition to the effects on LDL cholesterol 
described in the companion paper13, we report for the first time, to our 
knowledge, that the β039 mutation is also significantly associated with 
increased total counts of white blood cells (and some subsets thereof) 
as well as platelet counts. These findings suggest that in heterozygous 
carriers this variant drives a broader increase in bone marrow–
derived blood cell counts. Speculatively, some of these effects, such as 
augmented leukocyte and neutrophil counts, might have provided 
protection against pathogens in addition to those causing malaria, 
thus increasing selection for the balanced polymorphism.
The detected variants provide candidate modifiers influencing the 
clinical status of patients with monogenic hemoglobin disorders. For 
example, we carried out a preliminary analysis of a small sample of 
306 patients with β-thalassemia homozygous for the β039 stop-gain 
mutation but showing very great heterogeneity in disease presentation 
and course. In addition to the variants described previously7–10, some 
variants detected in this study showed possible effects as modifiers 
of disease severity (Supplementary Note). However, the potential 
of these variants in helping to predict disease severity remains 
tentative without studies of larger sample sets. Nevertheless, the 
variants already add to the candidate targets for therapeutic inter-
vention in the widely prevalent inherited β-thalassemia and other 
hemoglobinopathies2.
URLs. SardiNIA project, https://sardinia.irp.nia.nih.gov/; 1000 
Genomes Project, http://www.1000genomes.org/; HumanExome 
BeadChip design, http://genome.sph.umich.edu/wiki/Exome_Chip_
Design; Immunochip, http://www.t1dbase.org/poster/the-immuno-
chip-custom-genotype-array/; Cardio-Metabochip, http://csg.sph.
umich.edu//kang/MetaboChip/; Human OmniExpress BeadChip, 
http://www.illumina.com/applications/genotyping/human-geno-
typing-arrays/omni-arrays.html; GenomeStudio software, http://
www.illumina.com/applications/microarrays/microarray-software/
genomestudio.html; MACH software, http://csg.sph.umich.edu/
abecasis/MACH/; Minimac software, http://genome.sph.umich.
edu/wiki/Minimac; zCall software, https://github.com/jigold/zCall/; 
IMPUTE v2 software, http://mathgen.stats.ox.ac.uk/impute/impute_
v2.1.0.html; Merlin (including Merlin-regress and Merlin-offline), 
http://csg.sph.umich.edu/abecasis/merlin/; EPACTS software, http://
genome.sph.umich.edu/wiki/EPACTS; Metal software, http://csg.sph.
umich.edu/abecasis/metal/; GWAS catalog, http://www.genome.gov/
gwastudies/; GRAIL software, https://www.broadinstitute.org/mpg/
grail/; Gene Ontology, http://geneontology.org/; Human Expression 
Atlas at BioGPS, http://biogps.org/; Pritchard eQTL browser, http://
eqtl.uchicago.edu/; R project, http://www.r-project.org/.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE	METHODS
Sample description. The population studied here included 6,921 individuals, 
representing >60% of the adult population of 4 villages in the Lanusei valley in 
Sardinia, Italy. These individuals are part of the SardiNIA project, a longitudi-
nal study including genetic and phenotypic data for 1,257 multigenerational 
families with more than 37,000 relative pairs. Details of phenotype assess-
ments for these samples have been published previously4. All participants gave 
informed consent to study protocols, which were approved by the Sardinian 
local research ethic committees: Comitato Etico di Azienda Sanitaria Locale 8, 
Lanusei (2009/0016600) and Comitato Etico di Azienda Sanitaria Locale 1, 
Sassari (2171/CE)) and by the NIH Office of Human Subject Research as 
governed by Italian institutional review board approval.
For whole-genome sequencing, we selected 1,122 individuals from the 
SardiNIA study and 998 individuals enrolled in case-control studies of mul-
tiple sclerosis and type 1 diabetes in Sardinia. Genomes were sequenced to 
an average coverage of 4.16-fold. Details on the sequencing protocol, data 
processing and variant calling can be found elsewhere56 and in the companion 
paper13. The 2,120 sequenced samples consisted of 695 complete and incom-
plete parent-offspring trios; to avoid over-representation of rare haplotypes 
during the imputation process, we considered only the parents from each 
trio—totaling 1,488 samples—when building our reference panel56 (see the 
companion paper13 for further details).
Part of the sequencing data used in this study are available through the 
database of Genotypes and Phenotypes (dbGaP), under the SardiNIA Medical 
Sequencing Discovery Project, study accession phs000313.v3.p2.
Genotyping and imputation. The four microarrays used to genotype the 
entire SardiNIA cohort were the Illumina Infinium HumanExome BeadChip, 
Immunochip, Cardio-Metabochip and HumanOmniExpress BeadChip. 
Genotyping was carried out according to the manufacturer’s protocols at the 
SardiNIA Project Laboratory (Lanusei, Italy), at the Technological Center–
Porto Conte Ricerche (Alghero, Italy) and at the National Institute on Aging 
Intramural Research Program Laboratory of Genetics (Baltimore, Maryland, 
USA). Genotypes were called using GenomeStudio (version 1.9.4) and refined 
using zCall (version 3)57. We applied standard per-sample quality control 
filters to remove samples with low call rates or for which the reported rela-
tionships and/or sex was discordant with the genetic data. The details of the 
quality control filters are described elsewhere56. Altogether, 890,542 autosomal 
markers and 16,325 X-linked markers were genotyped across the SardiNIA 
study samples. We selected for phasing and imputation only the 6,602 samples 
for which genotyping was successfully carried out on all 4 arrays.
The genotypes were phased using MACH software58, with 30 iterations 
of the haplotyping Markov chain and 400 states per iteration. We performed 
imputation using Minimac software59 and a reference panel including the hap-
lotypes from 1,488 Sardinian whole genomes56 (see the companion paper13). 
Variants with estimated imputation quality (RSQR) ≤0.3 or <0.8 were dis-
carded if the estimated MAF was ≥1% or 0.5–1%, respectively; variants with 
MAF <0.5% were kept only if genotyped. The RSQR thresholds for rare and 
low-frequency variants were more stringent than those proposed for other 
traits56 as they led to better genomic control parameters (1.001, 0.993 and 
0.985 for HbA1, HbA2 and fetal hemoglobin, respectively). We also performed 
imputation with the 1000 Genomes Project phase 3 (version 5)36 haplotype 
set and used the same thresholds to discard variants. The genomic control 
parameters for 1000 Genomes Project imputation were 1.050, 0.997 and 0.984 
for HbA1, HbA2 and fetal hemoglobin, respectively.
Association analysis. We performed association analyses with the concentra-
tions (g/dl) for all three hemoglobins as well as the percentages for HbA2 and 
HbF. HbA2 and HbF percentages were directly measured from high-performance 
liquid chromatography (HPLC), and HbA1, HbA2 and HbF concentrations 
(g/dl) were derived from total hemoglobin amounts measured by Coulter 
counter. As expected, the measurements in percentage and grams per deciliter 
were highly correlated for HbF (Spearman’s ρ = 0.99) and HbA2 (ρ = 0.85). 
The HbA1 percentage was not considered for genetic association because it 
was too highly correlated with both the HbA2 and HbF percentages as a con-
sequence of their derivation formulas (ρ = −0.803 and −0.757, respectively; 
P < 1 × 10−20). Considering only non-carriers of β0 mutations, HbA1 (g/dl) was 
highly correlated with HbA2 (g/dl) (ρ = 0.662; P < 1 × 10−20) and poorly cor-
related with HbF (g/dl) (ρ = −0.055; P = 3.44 × 10−5). Likewise, HbA2 and HbF 
were weakly positively correlated as percentage measures (ρ = 0.108; P = 4.08 
× 10−16) and were even less correlated when measured in grams per deciliter 
(ρ = 0.066; P = 5.81 × 10−5), consistent with previous findings5. Measurements 
were available for a subset of 6,305 individuals; descriptive statistics are 
reported in Supplementary Table 1. Association results were considered 
genome-wide significant when the P value was <5 × 10−8; however, we also 
note in the text variants that would not meet a threshold of P = 1.4 × 10−8 
that we introduced for sequencing-based GWAS carried out in Sardinians for 
variants with MAF >0.5% (see the companion paper13).
Before association analyses, trait measures were normalized using inverse 
normal transformation; we also removed for all assessed traits outliers with 
values above 5% for HbF. Analyses were adjusted for age, age2 and sex as well 
as for the presence of at least one of the three β0 mutations (β039 (rs11549407), 
HBB c.20delA (rs63749819) and HBB c.315+1G>A (rs33945777)), all directly 
genotyped or sequenced. Regression coefficients for the β039 variant—the 
most common in Sardinia, with 10.3% of the population being a carrier—are 
reported in Supplementary Table 2.
Association was performed using the q.emmax test in EPACTS60, which 
implements a linear mixed-model procedure to correct for cryptic related-
ness and population stratification by incorporating a genomic-based kinship 
matrix. The associations reported in Table 1 refer to the best P value obtained 
with either percentage or original measurement units for HbA2 and HbF. 
Notably, HbF signals always resulted in lower P values when considering 
measurements in grams per deciliter, whereas, for HbA2 analysis, this was 
only the case for rs141494605. All loci passed the genome-wide significance 
threshold of P < 5 × 10−8 for both percentage and grams per deciliter except for 
rs59329875, which was genome-wide significant only for the HbA2 measure 
reported in Table 1.
To identify independent signals, we performed regional conditional analysis, 
using a forward selection procedure that added, at each step, the most associated 
variant as a covariate in the model. In this sequential analysis, we tested only 
SNPs lying in a 2-Mb region centered on the lead variant. The same genome-wide 
significance threshold used for primary signals was also considered for inde-
pendent signals. For loci where different independent signals were found, we also 
report the model parameters of the jointly associated variants in Supplementary 
Table 3. Finally, the lead variants and their surrogates (r2 >0.90) were annotated 
with CADD scores14 and are reported in Supplementary Table 5.
Heritability and variance explained. We estimated heritability for the three 
hemoglobins using Merlin-regress61 on the same sample used for the GWAS. 
The estimates for normalized hemoglobin levels were 0.520 g/dl for HbA1, 
0.728% for HbA2 (0.700 g/dl) and 0.633% for HbF (0.624 g/dl). We then 
calculated for each hemoglobin form the proportion of phenotypic variance 
explained by the associated lead variants. We measured this proportion as the 
difference in the R2-adjusted parameter estimated for the full and the basic 
models, where the basic model included only phenotypic covariates (age, age2 
and sex) and the full model also included all the independent SNPs associated 
with the specific trait. R2-adjusted values were calculated using a linear mixed-
model procedure from the lmekin() function in the kinship R package62. The 
estimates were 0.240 g/dl for HbA1, 0.492% for HbA2 and 0.383% for HbF.
Characterization of β0 mutations. For the present study, we designed a 
TaqMan custom assay for the HBB c.118C>T nonsense mutation (rs11549407, 
also known as β039) and genotyped 6,602 samples. Comparison of the TaqMan 
genotypes and the imputation results (rs11549407, RSQR = 0.92) showed an 
overall concordance rate of 98.8%. Also, we further sequenced all samples 
discordant between red blood cell index-based diagnosis (using mean corpus-
cular volume (MCV), mean corpuscular hemoglobin (MCH), HbF percentage 
and HbA2 percentage) and TaqMan genotypes, using Sanger sequencing to 
determine any additional β-globin mutations different from β039, thus iden-
tifying three carriers for the HBB c.20delA (rs63749819) mutation and one 
carrier for the HBB c.315+1G>A (rs33945777) mutation.
Characterization of the deletion in the α-globin gene cluster. In Sardinia, 
three variants are known to be mainly responsible for α-thalassemia: SNPs 
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rs111033603 and rs41474145 and the deletion g.34164_37967del3804 
(NG_000006.1); the latter, known as –α 3.7 deletion type I, is by far the most 
common63. We did not observe the rarer rs111033603 and rs41474145 SNPs 
in our sequencing effort. To establish genotypes at the deletion site in the 
full cohort, we used an inference strategy combined with experimental data. 
Specifically, we first characterized the structural variant by PCR in 260 unre-
lated sequenced individuals randomly selected from the SardiNIA cohort. 
We calculated the relative coverage of the deleted region in the whole genome–
sequenced samples by considering the ratio of read counts in the potentially 
deleted region (223,450–226,953 bp, excluding 150-bp boundaries) with read 
counts in the nearby region not subject to deletion (227,254–230,757 bp). We 
then identified coverage ratio thresholds that best predicted PCR genotypes 
for the deletion and used these thresholds to infer genotypes for the 2,120 
sequenced individuals. We inserted the genotypes in the Sardinian refer-
ence panel and imputed the deletion genotype for the total SardiNIA cohort. 
To assess the accuracy of imputation, we considered the best-guess genotypes 
and searched for Mendelian errors in families. The observed error rate was 
0.58% over 1,193 parent-offspring pairs, consistent with high imputation pre-
cision. The association results reported in the manuscript for this locus are 
corrected for inferred –α 3.7 deletion type I dosages.
Variant validation. We validated all variants that showed genome-wide 
significant P values in the primary or conditional analysis that were not directly 
genotyped or had no surrogates (r2 >0.90) that were directly genotyped. 
We did not validate variant rs13019832 in BCL11A for HbF, which was highly 
linked with findings from previous reports (rs7606173)49,51. Validation was 
performed using Sanger sequencing or TaqMan genotyping, depending on the 
variant frequency, for five variants. We selected for each variant all individuals 
carrying the minor allele (heterozygous and homozygous) plus a random sub-
set of individuals homozygous for the other allele (in all, 3,084 subjects were 
genotyped), except for rs141494605 and chr16:391593, for which we specifi-
cally selected worse imputation dosages (borderline RSQR values). In addition, 
for rs17525396, we used independent genotypes available for a subset of the 
cohort64, derived from Affymetrix 6.0 arrays (Supplementary Table 4).
Replication of variant effects. Replication was performed in the TwinsUK 
cohort43. Genotyping was performed using a combination of Illumina arrays 
(HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M), and impu-
tation was performed using the IMPUTE software package (v2) and 1000 
Genomes Project haplotypes released on 16 June 2014 in the phase 1 inte-
grated variant set release36,65. Details on quality control filters are provided 
in the Supplementary Note. HbA2 concentrations and HbF percentages were 
obtained by HPLC, and F cells were enumerated by staining for intracellular 
HbF and subsequent flow cytometry66. Measurements were available for 4,131 
samples. Association analyses were performed with the Merlin-offline pack-
age in Merlin, to account for relatedness61. To be consistent with analyses 
performed in the SardiNIA study, age, age2 and sex were used as covariates and 
the trait measures were transformed using quantile normalization.
Selection of candidate genes. At each locus, we generated a list of genes to 
be considered as plausible candidates, including those that satisfied one of 
the following criteria: (i) genes that were located within 25 kb of the lead SNP 
(indicated by p in Table 1); (ii) genes with exonic variants (frameshift, stop 
codon, nonsynonymous or synonymous) along with splice-site and 5′ or 3′ 
UTR variants in LD (r2 ≥ 0.8) with the lead SNP (indicated by c in Table 1); 
(iii) genes whose expression was modulated by the SNP itself or by an eQTL 
in LD (r2 ≥ 0.8) with the top SNP (indicated by e in Table 1); (iv) genes with a 
clear biological function connected with the traits (indicated by b in Table 1); 
or (v) genes harboring variants responsible for Mendelian diseases, as 
reported in OMIM (indicated by o in Table 1). We searched for candidate 
genes in eQTL data using an automatized pipeline querying 16 public eQTL 
repositories48,67–81, including the Pritchard eQTL browser; only top SNP 
eQTLs or SNPs with a false discovery rate (FDR) <0.05 were considered.
Pleiotropy and gene connection analysis. To characterize genome-wide 
significant results and to identify suggestively significant ones, we searched 
for shared effects on the different hemoglobin forms as well as evidence of 
connections between them. Specifically, for genome-wide significant markers, 
we have simply reported the effect direction for all traits with P < 0.01 when 
a marker was associated at the genome-wide level for one trait (Table 1). 
To identify candidates with suggestive P values between 1.00 × 10−4 and 
5.00 × 10−8, we selected among the following: (i) markers with MAF >0.5% 
and showing two-trait combined P values <5 × 10−8 (P values were combined 
using inverse variance–weighted meta-analysis, as implemented in Metal 
software82) and (ii) markers located in or near genes that demonstrated evi-
dence of connections with genome-wide significant loci, either in PubMed 
(using a set with data from 2006 or earlier to avoid confounding by subsequent 
GWAS discoveries) or the Human Expression Atlas37 and Gene Ontology38 
databases, as determined using GRAIL39, and considering genes reported with 
multiple hypothesis–corrected P < 0.05. Using these criteria, we identified 21 
further genes with biological connections to the genome-wide significant loci, 
reported in Supplementary Table 8, and 14 variants with combined P values 
between 2.08 × 10−8 and 1.18 × 10−11, reported in Supplementary Table 9.
56. Pistis, G. et al. Rare variant genotype imputation with thousands of study-specific 
whole-genome sequences: implications for cost-effective study designs. Eur. J. Hum. 
Genet. 23, 975–983 (2015).
57. Goldstein, J.I. et al. zCall: a rare variant caller for array-based genotyping: genetics 
and population analysis. Bioinformatics 28, 2543–2545 (2012).
58. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence 
and genotype data to estimate haplotypes and unobserved genotypes. Genet. 
Epidemiol. 34, 816–834 (2010).
59. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and 
accurate genotype imputation in genome-wide association studies through pre-
phasing. Nat. Genet. 44, 955–959 (2012).
60. Kang, H.M. et al. Variance component model to account for sample structure in 
genome-wide association studies. Nat. Genet. 42, 348–354 (2010).
61. Abecasis, G.R., Cherny, S.S., Cookson, W.O. & Cardon, L.R. Merlin—rapid analysis of 
dense genetic maps using sparse gene flow trees. Nat. Genet. 30, 97–101 (2002).
62. R Core Development Team. R: A Language and Environment for Statistical Computing 
(R Foundation for Statistical Computing, 2013).
63. Origa, R. et al. Complexity of the α-globin genotypes identified with thalassemia 
screening in Sardinia. Blood Cells Mol. Dis. 52, 46–49 (2014).
64. Naitza, S. et al. A genome-wide association scan on the levels of markers of 
inflammation in Sardinians reveals associations that underpin its complex regulation. 
PLoS Genet. 8, e1002480 (2012).
65. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation 
method for the next generation of genome-wide association studies. PLoS Genet. 
5, e1000529 (2009). 
66. Menzel, S. et al. A QTL influencing F cell production maps to a gene encoding a 
zinc-finger protein on chromosome 2p15. Nat. Genet. 39, 1197–1199 (2007).
67. Myers, A.J. et al. A survey of genetic human cortical gene expression. Nat. Genet. 
39, 1494–1499 (2007).
68. Stranger, B.E. et al. Population genomics of human gene expression. Nat. Genet. 
39, 1217–1224 (2007).
69. Veyrieras, J.-B. et al. High-resolution mapping of expression-QTLs yields insight 
into human gene regulation. PLoS Genet. 4, e1000214 (2008).
70. Dimas, A.S. et al. Common regulatory variation impacts gene expression in a cell 
type–dependent manner. Science 325, 1246–1250 (2009).
71. Pickrell, J.K. et al. Understanding mechanisms underlying human gene expression 
variation with RNA sequencing. Nature 464, 768–772 (2010).
72. Fehrmann, R.S.N. Trans-eQTLs reveal that independent genetic variants associated 
with a complex phenotype converge on intermediate genes, with a major role for 
the HLA. PLoS Genet. 7, e1002197 (2011).
73. Innocenti, F. et al. Identification, replication, and functional fine-mapping of 
expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7, 
e1002078 (2011).
74. Montgomery, S.B., Lappalainen, T., Gutierrez-Arcelus, M. & Dermitzakis, E.T. Rare 
and common regulatory variation in population-scale sequenced human genomes. 
PLoS Genet. 7, e1002144 (2011).
75. Degner, J.F. et al. DNaseI sensitivity QTLs are a major determinant of human 
expression variation. Nature 482, 390–394 (2012).
76. Gaffney, D.J. et al. Dissecting the regulatory architecture of gene expression QTLs. 
Genome Biol. 13, R7 (2012).
77. Wright, F.A., Shabalin, A.A. & Rusyn, I. Computational tools for discovery and interpretation 
of expression quantitative trait loci. Pharmacogenomics 13, 343–352 (2012).
78. Lappalainen, T. et al. Transcriptome and genome sequencing uncovers functional 
variation in humans. Nature 501, 506–511 (2013).
79. Westra, H.-J. et al. Systematic identification of trans eQTLs as putative drivers of 
known disease associations. Nat. Genet. 45, 1238–1243 (2013).
80. Battle, A. et al. Characterizing the genetic basis of transcriptome diversity through 
RNA-sequencing of 922 individuals. Genome Res. 24, 14–24 (2014).
81. Fairfax, B.P. et al. Innate immune activity conditions the effect of regulatory variants 
upon monocyte gene expression. Science 343, 1246949 (2014).
82. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
